[1] P. Gaona-luviano, L. A. Medina-gaona, and K. Magaña-pérez, “Epidemiology of ovarian cancer,” Chinese Clin. Oncol., vol. 9, no. 4, p. 47, 2020, doi: 10.21037/cco-20-34.
[2] A. J. Alberg et al., “Socioeconomic Status in Relation to the Risk of Ovarian Cancer in African-American Women: A Population-Based Case-Control Study,” Am. J. Epidemiol., vol. 184, no. 4, pp. 274–283, 2016, doi: 10.1093/aje/kwv450.
[3] I. Pity et al., “Ovarian Epithelial Cancers: A Pathological Study of 164 Cases,” Al- Anbar Med. J., vol. 20, no. 2, pp. 200–206, Sep. 2024, doi: 10.33091/amj.2024.150051.1732.
[4] A. Bounin, B. Charbotel, B. Fervers, and A. Bergeret, “Facteurs de risques professionnels du cancer de l’ovaire. Revue de la littérature,” Bull. Cancer, vol. 101, no. 12, pp. 1089–1108, Dec. 2014, doi: 10.1684/bdc.2014.1978.
[5] S. Y. Pan, A. Ugnat, Y. Mao, S. W. Wen, and K. C. Johnson, “Association of cigarette smoking with the risk of ovarian cancer,” Int. J. Cancer, vol. 111, no. 1, pp. 124–130, Aug. 2004, doi: 10.1002/ijc.20242.
[6] J. A. Baker, O. O. Odunuga, K. Rodabaugh, M. Reid, R. Menezes, and K. Moysich, “Active and passive smoking and risk of ovarian cancer,” Int. J. Gynecol. Cancer, vol. 16, no. (suppl. 1), pp. 211–218, Jan. 2006, doi: 10.1136/ijgc-00009577-200602001-00034.
[7] J. Kruk, B. H. Aboul-Enein, J. Bernstein, and M. Gronostaj, “Psychological Stress and Cellular Aging in Cancer: A Meta-Analysis,” Oxid. Med. Cell. Longev., vol. 2019, no. 1, pp. 1–23, Nov. 2019, doi: 10.1155/2019/1270397.
[8] P. Brady, “CA125 and Ca Ovarium, Comprehensive review,” Shipp. World Shipbuild., vol. 208, no. 4233, pp. 46–48, 2020.
[9] M. Shetty, “Imaging and Differential Diagnosis of Ovarian Cancer,” Semin. Ultrasound, CT MRI, vol. 40, no. 4, pp. 302–318, 2019, doi: 10.1053/j.sult.2019.04.002.
[10] S. Rao et al., “Past, present, and future of serum tumor markers in management of ovarian cancer: A guide for the radiologist,” Radiographics, vol. 41, no. 6, pp. 1839–1856, 2021, doi: 10.1148/RG.2021210005.
[11] M. Vali et al., “Survival rate of cervical cancer in Asian countries: a systematic review and meta-analysis,” BMC Womens. Health, vol. 23, no. 1, pp. 1–11, 2023, doi: 10.1186/s12905-023-02829-8.
[12] R. Ahmed, “Risk factors among patients with ovarian cancer attending oncology hematology center in Basrah city,” Basrah J. Surg., vol. 28, no. 1, pp. 18–24, 2022, doi: 10.33762/bsurg.2022.132631.1017.
[13] S. Franjić, “Ovarian Cancer is the Deadliest of all Gynecological Tumors,” Mathews J. Gynecol. Obstet., vol. 7, no. 1, p. 22, Jan. 2023, doi: 10.30654/MJGO.10022.
[14] S. Zhang et al., “The global burden and associated factors of ovarian cancer in 1990–2019: findings from the Global Burden of Disease Study 2019,” BMC Public Health, vol. 22, no. 1, p. 1455, Dec. 2022, doi: 10.1186/s12889-022-13861-y.
[15] A. T. Ali, O. Al-Ani, and F. Al-Ani, “Epidemiology and risk factors for ovarian cancer,” Prz. Menopauzalny, vol. 22, no. 2, pp. 93–104, 2023, doi: 10.5114/pm.2023.128661.
[16] A. Buckler and P. Luu, “Screening for ovarian cancer,” Am. Fam. Physician, vol. 87, no. 10, pp. 709–710, 2013.
[17] D. W. Cramer, “Incessant ovulation: a review of its importance in predicting cancer risk,” Front. Oncol., vol. 13, no. 10, pp. 1–10, 2023, doi: 10.3389/fonc.2023.1240309.
[18] C. Trudel-Fitzgerald et al., “Social Integration, Marital Status, and Ovarian Cancer Risk: A 20-Year Prospective Cohort Study,” Psychosom. Med., vol. 81, no. 9, pp. 833–840, 2019, doi: 10.1097/PSY.0000000000000747.
[19] V. Toufakis, S. Katuwal, E. Pukkala, and J. S. Tapanainen, “Impact of parity on the incidence of ovarian cancer subtypes: a population-based case–control study,” Acta Oncol. (Madr)., vol. 60, no. 7, pp. 850–855, 2021, doi: 10.1080/0284186X.2021.1919754.
[20] Y. Y. Xia and J. Kotsopoulos, “Beyond the pill: contraception and the prevention of hereditary ovarian cancer,” Hered. Cancer Clin. Pract., vol. 20, no. 1, pp. 1–9, 2022, doi: 10.1186/s13053-022-00227-z.
[21] A. I. Gaia‑Oltean et al., “Ovarian endometriosis, a precursor of ovarian cancer: Histological aspects, gene expression and microRNA alterations (Review),” Exp. Ther. Med., vol. 21, no. 3, p. 243, Jan. 2021, doi: 10.3892/etm.2021.9674.
[22] J. A. Ross, “Contraceptive Use, Access to Methods, and Program Efforts in Urban Areas,” Front. Glob. Women’s Heal., vol. 2, no. 6, p.65-81, Sep. 2021, doi: 10.3389/fgwh.2021.636581.
[23] Asheeka Zainab Arif, Balaji Ramraj, Swapna Kiran, and Balasandhiya Prabakar, “Study of awareness, attitude, and utilization of Complementary and Alternative Medicine among patients visiting urban and rural health centers,” Int. J. Res. Pharm. Sci., vol. 11, no. SPL4, pp. 2662–2668, Dec. 2020, doi: 10.26452/ijrps.v11iSPL4.4537.
[24] A. F. Abbas, “ Risk Factors and Symptoms of Ovarian Cancer in Patients Attending Hiwa Oncology / Hematology Hospital in Sulaimaniyah City”. Kufa journal for nursing sciences.; vol. 11, no. 2, p. 1-11, 2021.
[25] D. Szpurek, R. Moszynski, S. Szubert, and S. Sajdak, “Urban and rural differences in characteristics of ovarian cancer patients,” Ann. Agric. Environ. Med., vol. 20, no. 2, pp. 390–394, 2013.
[26] S. A. A. Ahmed and S. Yassien, “Risk and Protective Factors Associated with Ovarian Cancer among Two Egyptian Cohorts,” Evidence-Based Nurs. Res., vol. 1, no. 2, p. 14, Jun. 2019, doi: 10.47104/ebnrojs3.v1i2.40.
[27] Z. Momenimovahed, A. Tiznobaik, S. Taheri, and H. Salehiniya, “Ovarian cancer in the world: Epidemiology and risk factors,” Int. J. Womens. Health, vol. 11, no. 1, pp. 287–299, 2019, doi: 10.2147/IJWH.S197604.
[28] S. K. Myung et al. Mobile phone use and risk of tumors: a meta-analysis. Journal of clinical oncology, 27(33):5565–5572, 2009. doi: 110.1200/JCO.2008.21.6366.
[29] B. Guldiken, G. Ozkan, G. Catalkaya, F. D. Ceylan, I. Ekin Yalcinkaya, and E. Capanoglu, “Phytochemicals of herbs and spices: Health versus toxicological effects,” Food Chem. Toxicol., vol. 119, no. 1, pp. 37–49, 2018, doi: 10.1016/j.fct.2018.05.050.
[30] J. E. Vena, “Lung, Breast, Bladder and Rectal Cancer,” Rev. Environ. Health, vol. 25, no. 1, pp. 39–46, Jan. 2010, doi: 10.1515/REVEH.2010.25.1.39.
[31] K. Jin Shin et al., “Molecular Mechanisms Underlying Psychological Stress and Cancer,” Curr. Pharm. Des., vol. 22, no. 16, pp. 2389–2402, Apr. 2016, doi: 10.2174/1381612822666160226144025.
[32] C. Cosentino and C. A. Pruneti, “Towards an integrated model of defense in gynecological cancer. Psychoneuroimmunological and psychological factors, between risk and protection in cancer: A review,” Integr. Cancer Sci. Ther., vol. 2, no. 2, pp. 112–117, 2015, doi: 10.15761/ICST.1000125.
[33] S. Shabir and P. K. Gill, “Global scenario on ovarian cancer – Its dynamics, relative survival, treatment, and epidemiology,” Adesh University Journal of Medical Sciences & Research, vol. 2.,no. 1, pp. 17–25, 2020. doi: 10.25259/aujmsr_16_2019.